Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013
Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013
复制标题
DOI：
10.1016/j.mayocp.2013.01.019
复制
发表时间：
2013-04-01
影响因子：
8.9
通讯作者：
Lacy, Martha Q.
中科院分区：
文献类型：
--
作者：
Mikhael, Joseph R.;Dingli, David;Lacy, Martha Q.
多发性骨髓瘤仍然是一种不可治愈的浆细胞肿瘤，在美国每年影响超过20，000人。在过去的十年中，这种疾病发生了真正的革命，我们对其发病机制的理解有了巨大的进步，开发了几种新型药物，总体生存率也随之增加了一倍。由于多发性骨髓瘤是一种复杂和广泛的疾病，其管理必须由疾病和患者相关因素指导;最具影响力的因素之一是风险分层，主要基于细胞遗传学特征。风险适应性方法为患者提供最佳治疗，确保对侵袭性疾病进行强化治疗，并将毒性作用降至最低，为低风险疾病提供充分但强度较低的治疗。这一共识声明反映了20多位马约诊所骨髓瘤医生的建议，为未参加临床试验的新诊断骨髓瘤患者提供了一种实用的方法。(C)2013年马约医学教育和研究基金会广场马约临床学报2013; 88（4）：360-376
Multiple myeloma remains an incurable neoplasm of plasma cells that affects more than 20,000 people annually in the United States. There has been a veritable revolution in this disease during the past decade, with dramatic improvements in our understanding of its pathogenesis, the development of several novel agents, and a concomitant doubling in overall survival. Because multiple myeloma is a complex and wide-ranging disorder, its management must be guided by disease- and patient-related factors; emerging as one of the most influential factors is risk stratification, primarily based on cytogenetic features. A risk-adapted approach provides optimal therapy to patients, ensuring intense therapy for aggressive disease and minimizing toxic effects, providing sufficient but less intense therapy for low-risk disease. This consensus statement reflects recommendations from more than 20 Mayo Clinic myeloma physicians, providing a practical approach for newly diagnosed patients with myeloma who are not enrolled in a clinical trial. (C) 2013 Mayo Foundation for Medical Education and Research square Mayo Clin Proc. 2013; 88(4): 360-376